Clinical Trial Update: A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of oral LBH589 (panobinostat) in adults with advanced hematologic malignancies completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• LBH589 (panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lymphoma, Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-08-17